Lapovis Plus

Latanoprost and Timolol, the active ingredients in Lapovis Plus, are a prostaglandin analog and a non‑selective beta‑blocker presented as eye drops for ocular use. They are indicated for the management of elevated intra‑ocular pressure in open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Lapovis Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution. All shipments are handled under controlled temperature conditions to preserve product integrity.

Lapovis Plus combines a prostaglandin analog and a beta‑blocker to lower intra‑ocular pressure in glaucoma‑related conditions.

Open‑angle glaucoma: provides a dual mechanism that reduces aqueous humor production and enhances outflow, achieving a sustained decrease in intra‑ocular pressure and helping to preserve visual field. Ocular hypertension: lowers elevated eye pressure in patients without optic nerve damage, reducing the risk of developing glaucoma over time. Secondary open-angle glaucoma: offers effective pressure control in cases where other therapies are insufficient, supporting optic nerve health alongside standard treatments.

Eye drops containing latanoprost and timolol may be associated with ocular and systemic adverse reactions.

Common Side Effects: - Eye redness: transient hyperemia of the conjunctiva. - Eye irritation or foreign‑body sensation. - Blurred vision: temporary reduction in visual clarity. - Increased eyelash growth or darkening of the iris. - Dry eye: decreased tear production. - Mild eye discharge: occasional tearing or watery eyes.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or anaphylaxis. - Acute angle‑closure glaucoma: sudden eye pain and vision loss. - Systemic bradycardia or hypotension: especially in patients with cardiac disease.

When prescribing Lapovis Plus, clinicians should consider several precautionary measures to ensure patient safety. - Assess cardiovascular status: avoid use in patients with severe bradycardia or heart block. - Review respiratory history: contraindicated in patients with asthma or chronic obstructive pulmonary disease. - Monitor intra‑ocular pressure: check pressure response after initiation and adjust therapy as needed. - Avoid contact lens wear: discontinue lenses for at least 15 minutes after instillation. - Discontinue if allergic reaction occurs: stop treatment and seek medical attention. - Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost/timolol eye drops can interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Systemic non‑selective β‑blockers (e.g., propranolol): may cause additive bradycardia or hypotension. - Other prostaglandin analogues: concurrent use can increase risk of ocular hyperemia and iris pigmentation. - Sympathomimetic eye drops (e.g., phenylephrine): may reduce the intra‑ocular pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitors (e.g., dorzolamide): additive pressure‑lowering effect may require dose adjustment. - Anticholinergic eye drops: may affect pupil size and comfort.